Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year~* Participants must be using Continuous Glucose Monitoring (CGM) with total CGM use ≥ 2 months in the prior 6 months~* Participants must have been on the same type of short acting insulin (Humalog U-100, Novolog, Admelog, or Apidra) for at least 30 days prior to screening~* Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening~Exclusion Criteria:~* Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening~* Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening~* Participants must not be taking certain diabetes medications that are not allowed for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LY900014 + Insulin Degludec (Type: EXPERIMENTAL): LY900014 (100 units/milliliter (U/mL)) is a prandial insulin administered subcutaneously (SC) 0-2 minutes before meals. Insulin degludec (100 U/mL) is a basal insulin administered once daily SC. Participants received individually adjusted insulin doses during the 35-day titration period. The target glucose values were: fasting glucose 80-110 milligrams per deciliter (mg/dL), overnight glucose excursion (the difference between bedtime and prebreakfast glucose levels) \< or = +/- 30 mg/dL, postprandial glucose peak \<140 mg/dL or \<20% increase from premeal level. Following the titration period, there was an 11-day maintenance period during which the doses were kept unchanged unless for safety reasons.

Based on this trial design, predict the completion outcome and termination type (if applicable).